newsfilter
← Latest News
GlobeNewswire·

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

  • Exicure, Inc. received a non-compliance notice from Nasdaq on May 28, 2026, for failing to file its Q1 2026 Form 10-Q by the deadline.
  • The delay was caused by changes in financial reporting personnel & related filing procedures.
  • The company filed the delayed Q1 2026 Form 10-Q with the SEC on May 29, 2026.
  • Exicure believes it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing.
  • Exicure is an early-stage biotechnology firm that acquired a clinical-stage company in January 2025 & is exploring strategic alternatives after restructuring.
  • The company's lead program targets stem cell mobilization for multiple myeloma, sickle cell disease, & cell & gene therapy support.